The REACH publication library
Discovery, documented.
Explore 101 REACH publication records—from fundamental biology to clinical research.
The library includes journal articles, preprints, and a book chapter supported by REACH. It contains 18 preprints and 12 linked preprint–journal pairs; versions are separate records, not independent studies.
The October 12, 2026 check reconciled all 98 records in PubMed’s AI164565 grant-number search. Three additional records have verified REACH award acknowledgments. The original NIH RePORTER collection contained 93 records when retrieved on September 7, 2026.
Showing all 101 records
Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
Fumagalli MJ; Kaczynska A; Allombert M; Lopes-Ribeiro Á; de Oliveira Silva M; Hernandez BJ; et al.
Nature Medicine · 2026 Sep 15
Journal article · REACH award acknowledgment verified
Fc-engineered broadly neutralizing antibodies overcome cytokine-induced CD16 cleavage to drive potent ADCC against diverse HIV-1 strains.
Melo C; Murphy T; Holmberg CS; Kelly M; McMahon EK; Lochner JS; Lynch RM; Bosque A
mBio · 2026 Aug 21 · First published online
Journal article · REACH award acknowledgment verified
HIV superinfection reveals sequential reservoir reactivation and immune-driven rebound dynamics.
Omondi FH; Shahid A; Kinloch NN; Dong W; Duncan MC; Yaseen F; et al.
Journal of virology · 2026 Aug 18
Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.
Fisher K; Garcia MA; Frattari GS; Naasz C; Zhuo J; Rosás-Umbert M; et al.
Nature immunology · 2026 Apr
What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.
Teixeira AR; Caskey M
The Journal of infectious diseases · 2026 Jun 16
Dynamic antigen expression and cytotoxic T cell resistance in HIV reservoir clones.
Ferreira IATM; Herrera A; Huynh TT; Stone E; Linden NL; Ovies C; et al.
Nature · 2026 May
Q4ddPCR: a flexible, 4-target assay for high-resolution HIV reservoir profiling.
Scheck R; Melzer M; Gladkov G; Leyre L; Ward AR; Reeves DB; et al.
Nature communications · 2026 Feb 20
Retinoids enhance NK effector function against HIV-infected CD4 T cells.
McMahon EK; Lochner JS; Lynch RM; Bosque A
Journal of virology · 2026 Feb 17
Development and validation of HIV SMRTcap for the characterization of HIV-1 reservoirs across tissues and subtypes.
Sadri G; Nadakal ST; Lauer W; Kos J; Singh PK; Elliott E; et al.
PLoS pathogens · 2026 Jan
PRISM-Seq: An Ultra-sensitive Sequencing Approach For Mapping Lentiviral Integration Sites.
Pal VK; Canis M; Stone E; Board NL; Lenart K; Fumagalli MJ; et al.
bioRxiv : the preprint server for biology · 2026 Feb 07
HIV-1 Integration Site Determines the Transcriptional Fate and Persistence of Integrated Proviruses.
Pal VK; Danesh A; Canis M; Dilling TR; Miller IG; Huynh TT; et al.
bioRxiv : the preprint server for biology · 2026 Feb 07
Transcription of HIV-1 is heterogenous among authentic latent CD4+ T cell clones.
Bittar C; Teixeira AR; Oliveira TY; Silva Santos GS; Lenart K; Fumagalli MJ; et al.
The Journal of experimental medicine · 2026 Mar 02
HIV-1 transcription dominates over host gene activity at the HIV-1 integration site.
Weissman S; Yeh Y-HJ; Viazmenski M; Kim R; Collora JA; Steinhauser S; et al.
mBio · 2026 Jan 14
Early immune responses anticipate HIV rebound and precede viral control.
Farrell-Sherman A; Azam W; de la Force N; White EL; Sandel DA; Rodriguez AE; et al.
bioRxiv · 2026 Mar 25
Preprint · REACH grant indexed in PubMed
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation.
Gaebler C; Kor S; Allers K; Perotti M; Mwangi D; Meixenberger K; et al.
Nature · 2026 Feb · 650:701–709 · First published online December 1, 2025
Journal article · REACH award acknowledgment verified
Non-suppressible HIV viremia sustained by clonally expanded CD4+ T cells harboring a genomically defective provirus with an immune-evasive protein expression profile.
Omondi FH; Sang Y; Dong W; Mwimanzi F; Cheung PK; Barad E; et al.
mBio · 2026 May 13 · 17(5):e03909-25 · First published online March 30, 2026
Journal article · REACH award acknowledgment verified
Loss of Vpr-driven TRAIL-R2 expression protects HIV-infected cells from non-canonical NK cell TRAIL attack.
Grasberger PE; Sondrini AR; Glidden N; Modica A; Pushlar N; Bedir S; et al.
bioRxiv · 2026 Apr 19
Preprint · REACH award acknowledgment verified
HIV Nef amplifies mechanical heterogeneity to promote immune evasion.
Leyre L; Mustapha F; Herrera A; Lee E; Huntsman E; Zumbo P; et al.
bioRxiv : the preprint server for biology · 2025 Dec 26
Within-Subtype HIV-1 Polymorphisms and Their Impacts on Intact Proviral DNA Assay (IPDA) for Viral Reservoir Quantification.
Arikatla MR; Mathad JS; Reddy K; Reddy N; Ndung'u T; Dupnik KM; et al.
Viruses · 2025 Oct 31
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.
Fumagalli MJ; Kaczynska A; Allombert M; Lopes-Ribeiro Á; de Oliveira Silva M; Hernandez BJ; et al.
medRxiv : the preprint server for health sciences · 2025 Nov 06
Targeting HIV myeloid and central nervous system reservoirs for HIV cure.
Grasberger P; Clayton KL
Current opinion in HIV and AIDS · 2025 Nov 01
HIV cure research contributions from Africa in the last three decades.
Nakanjako D; Kankaka EN; Lungu C; Galiwango RM; Reynolds SJ; Mahmoudi T; et al.
Frontiers in immunology · 2025
Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence.
Wei Y; Ma HK; Wong ME; Back H; Papasavvas E; Mounzer K; et al.
Immunity · 2025 Nov 11
A daisy chain of inferences: the role of single-cell and single-genome proviral sequencing in characterizing HIV-1 reservoirs.
Lee GQ
Current opinion in HIV and AIDS · 2025 Sep 01
Development and validation of HIV SMRTcap for the characterization of HIV-1 reservoirs across tissues and subtypes.
Sadri G; Nadakal ST; Lauer W; Kos J; Singh PK; Elliott EM; et al.
bioRxiv : the preprint server for biology · 2025 May 05
Roadmap for spatial transcriptomics of HIV in tissues.
Guan Q; Eshetu A; Ho YC
Current opinion in HIV and AIDS · 2025 Sep 01
AntiBMPNN: Structure-Guided Graph Neural Networks for Precision Antibody Engineering.
Sun ZY; Yuan J; Jaiswal D; Ge J; Liang T; Wei J; et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025 Sep
Prolonged non-suppressible viremia sustained by a clonally expanded, genomically defective provirus with an immune-evasive HIV protein expression profile.
Omondi FH; Sang Y; Mwimanzi F; Cheung PK; Derza Z; Dong W; et al.
bioRxiv : the preprint server for biology · 2025 May 16
Medications for opioid use disorder shape immune responses during chronic HIV infection.
Collora JA; Steinhauser SF; Davenport TC; Lin DC; Eshetu A; Zeidi S; et al.
Cell reports. Medicine · 2025 Jun 17
Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts.
Ehrenberg PK; Geretz A; Volcic M; Izumi T; Yum LK; Waickman A; et al.
Nature communications · 2025 May 29
EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes.
Gramatica A; Miller IG; Ward AR; Khan F; Kemmer TJ; Weiler J; et al.
Cell reports · 2025 May 27
Intact HIV DNA decays in children with and without complete viral load suppression.
Reeves DB; Litchford M; Fish CS; Farrell-Sherman A; Poindexter M; Ahmed N; et al.
PLoS pathogens · 2025 Apr
Association between HIV-1 Nef-mediated MHC-I downregulation and the maintenance of the replication-competent latent viral reservoir in individuals with virally suppressed HIV-1 in Uganda: an exploratory cohort study.
Mumby MJ; Prodger JL; Hackman J; Saraf S; Zhu X; Ferreira RC; et al.
The Lancet. Microbe · 2025 May
A simple phylogenetic approach to analyze hypermutated HIV proviruses reveals insights into their dynamics and persistence during antiretroviral therapy.
Shahid A; Jones BR; Duncan MC; MacLennan S; Dapp MJ; Kuniholm MH; et al.
Virus evolution · 2025
Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.
Rai MA; Blazkova J; Kardava L; Justement JS; Shi V; Manning MR; et al.
Nature medicine · 2025 Feb
Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies.
Pahus MH; Zheng Y; Olefsky M; Gunst JD; Tebas P; Taiwo B; et al.
The Journal of infectious diseases · 2025 Feb 20
A Participant-Derived Xenograft Mouse Model to Decode Autologous Mechanisms of HIV Control and Evaluate Immunotherapies.
Falling Iversen E; Miller IG; Søgaard O; Danesh A; Jones BR
Bio-protocol · 2025 Apr 5 · 15(7):e5254
Journal protocol article · REACH grant indexed in PubMed
BACH2-driven tissue resident memory programs promote HIV-1 persistence.
Wei Y; Ma HK; Wong ME; Papasavvas E; Konnikova L; Tebas P; et al.
bioRxiv : the preprint server for biology · 2024 Dec 20
Single-cell analyses reveal that monocyte gene expression profiles influence HIV-1 reservoir size in acutely treated cohorts.
Ehrenberg PK; Geretz A; Volcic M; Izumi T; Yum L; Waickman A; et al.
bioRxiv : the preprint server for biology · 2024 Nov 15
AI-based IsAb2.0 for antibody design.
Liang T; Sun ZY; Hines MG; Penrose KJ; Hao Y; Chu X; et al.
Briefings in bioinformatics · 2024 Jul 25
Transcription of HIV-1 at sites of intact latent provirus integration.
Teixeira AR; Bittar C; Silva Santos GS; Oliveira TY; Huang AS; Linden N; et al.
The Journal of experimental medicine · 2024 Sep 02
The HIV latency reversing agent HODHBt inhibits the phosphatases PTPN1 and PTPN2.
Howard JN; Zaikos TD; Levinger C; Rivera E; McMahon EK; Holmberg CS; et al.
JCI insight · 2024 Aug 08
HIV-1 subtype A1, D, and recombinant proviral genome landscapes during long-term suppressive therapy.
Lee GQ; Khadka P; Gowanlock SN; Copertino DC; Duncan MC; Omondi FH; et al.
Nature communications · 2024 Jul 02
A simple phylogenetic approach to analyze hypermutated HIV proviruses reveals insights into their dynamics and persistence during antiretroviral therapy.
Shahid A; Jones BR; Duncan MC; MacLennan S; Dapp MJ; Kuniholm MH; et al.
Research square · 2024 Jun 13
Impact of Variable Sampling on Estimates of HIV-1 Reservoir Formation Dates.
Kankaka EN; Poon AFY; Quinn TC; Chang LW; Prodger JL; Redd AD
The Journal of infectious diseases · 2024 Oct 16
Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.
Webb GM; Pessoa CT; McCullen AJ; Hwang JM; Humkey MC; Thormin-Odum R; et al.
Journal of virology · 2024 Jun 13
Transcription of HIV-1 at sites of intact latent provirus integration.
Teixeira AR; Bittar C; Silva Santos GS; Oliveira TY; Huang AS; Linden N; et al.
bioRxiv : the preprint server for biology · 2024 Apr 29
Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen.
Ferreira RC; Reynolds SJ; Capoferri AA; Baker OR; Brown EE; Klock E; et al.
EBioMedicine · 2024 Apr
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Lim SY; Lee J; Osuna CE; Vikhe P; Schalk DR; Chen E; et al.
Science (New York, N.Y.) · 2024 Mar 08
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
Duncan MC; Omondi FH; Kinloch NN; Lapointe HR; Speckmaier S; Moran-Garcia N; et al.
AIDS (London, England) · 2024 Jul 01
The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time.
Shahid A; MacLennan S; Jones BR; Sudderuddin H; Dang Z; Cobarrubias K; et al.
Journal of virology · 2024 Feb 20
Harnessing immune cells to eliminate HIV reservoirs.
Grasberger P; Sondrini AR; Clayton KL
Current opinion in HIV and AIDS · 2024 Mar 01
3D human tissue models and microphysiological systems for HIV and related comorbidities.
3D Human Tissue Models for HIV Working Group. Electronic address: dwight.yin@nih.gov; 3D Human Tissue Models for HIV Working Group
Trends in biotechnology · 2024 May
An Ultrasensitive p24 Assay to Measure HIV-1 in Diverse Biological Matrixes.
Levinger C; Natalie Howard J; Bosque A
Methods in Molecular Biology · 2024 · 2807:343–354
Book chapter · REACH grant indexed in PubMed
HIV reservoirs are dominated by genetically younger and clonally enriched proviruses.
Kinloch NN; Shahid A; Dong W; Kirkby D; Jones BR; Beelen CJ; et al.
mBio · 2023 Dec 19
Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence.
Wei Y; Davenport TC; Collora JA; Ma HK; Pinto-Santini D; Lama J; et al.
Immunity · 2023 Nov 14
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
Duncan MC; Omondi FH; Kinloch NN; Lapointe HR; Speckmaier S; Moran-Garcia N; et al.
medRxiv : the preprint server for health sciences · 2023 Oct 09
The latent HIV reservoir: current advances in genetic sequencing approaches.
Moar P; Premeaux TA; Atkins A; Ndhlovu LC
mBio · 2023 Oct 31
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV.
Matveev VA; Mihelic EZ; Benko E; Budylowski P; Grocott S; Lee T; et al.
iScience · 2023 Oct 20
Whack-a-virus: HIV-specific T cells play an exhausting game.
Herrera A; Jones RB
Cell host & microbe · 2023 Sep 13
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.
Gunst JD; Højen JF; Pahus MH; Rosás-Umbert M; Stiksrud B; McMahon JH; et al.
Nature medicine · 2023 Oct
The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time.
Shahid A; MacLennan S; Jones BR; Sudderuddin H; Dang Z; Cobamibias K; et al.
Research square · 2023 Aug 16
The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells.
Copertino DC; Holmberg CS; Weiler J; Ward AR; Howard JN; Levinger C; et al.
JCI insight · 2023 Sep 22
Dating reservoir formation in virologically suppressed people living with HIV-1 in Rakai, Uganda.
Kankaka EN; Redd AD; Khan A; Reynolds SJ; Saraf S; Kirby C; et al.
Virus evolution · 2023
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels.
Wong M; Wei Y; Ho YC
Current opinion in HIV and AIDS · 2023 Sep 01
The largest HIV-1-infected T cell clones in children on long-term combination antiretroviral therapy contain solo LTRs.
Botha JC; Demirov D; Gordijn C; Katusiime MG; Bale MJ; Wu X; et al.
mBio · 2023 Aug 31
Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV.
Ghofrani J; Bowen A; Chen J; Balakrishnan PB; Powell AB; Cherukula K; et al.
International journal of nanomedicine · 2023
Global HIV control: is the glass half empty or half full?
Nachega JB; Musoke P; Kilmarx PH; Gandhi M; Grinsztejn B; Pozniak A; et al.
The lancet. HIV · 2023 Sep
Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV.
Matveev VA; Mihelic EZ; Benko E; Budylowski P; Grocott S; Lee T; et al.
bioRxiv : the preprint server for biology · 2023 Jun 15
Impact of misclassified defective proviruses on HIV reservoir measurements.
Reeves DB; Gaebler C; Oliveira TY; Peluso MJ; Schiffer JT; Cohn LB; et al.
Nature communications · 2023 Jul 13
Integration site-dependent HIV-1 promoter activity shapes host chromatin conformation.
Collora JA; Ho YC
Genome research · 2023 Jun
Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen.
Ferreira RC; Reynolds SJ; Capoferri AA; Baker O; Brown EE; Klock E; et al.
medRxiv : the preprint server for health sciences · 2023 May 16
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary.
Sanders-Beer BE; Archin NM; Brumme ZL; Busch MP; Deleage C; O'Doherty U; et al.
AIDS research and human retroviruses · 2023 Jun 19
HIV reservoirs are dominated by genetically younger and clonally enriched proviruses.
Kinloch NN; Shahid A; Dong W; Kirkby D; Jones BR; Beelen CJ; et al.
bioRxiv : the preprint server for biology · 2023 Apr 13
Long-acting antiretrovirals and HIV treatment adherence.
Nachega JB; Scarsi KK; Gandhi M; Scott RK; Mofenson LM; Archary M; et al.
The lancet. HIV · 2023 May
bayroot: Bayesian sampling of HIV-1 integration dates by root-to-tip regression.
Ferreira RC; Wong E; Poon AFY
Virus evolution · 2023
Interferon opens up: HIV-induced inflammation reconfigures 3D chromatin conformation and affects where HIV integrates.
Wei Y; Ho YC
Molecular cell · 2022 Dec 15
HIV-1 replication and latency are balanced by mTOR-driven cell metabolism.
Crater JM; Nixon DF; Furler O'Brien RL
Frontiers in cellular and infection microbiology · 2022
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?
Caskey M; Kuritzkes DR
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022 Nov 21
HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy.
Shahid A; Jones BR; Yang JSW; Dong W; Shaipanich T; Donohoe K; et al.
PLoS pathogens · 2022 Nov
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity.
Rosás-Umbert M; Gunst JD; Pahus MH; Olesen R; Schleimann M; Denton PW; et al.
Nature communications · 2022 Oct 29
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
Gunst JD; Pahus MH; Rosás-Umbert M; Lu IN; Benfield T; Nielsen H; et al.
Nature medicine · 2022 Nov
Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins.
Zhang F; Zang TM; Stevenson EM; Lei X; Copertino DC; Mota TM; et al.
Proceedings of the National Academy of Sciences of the United States of America · 2022 Oct 11
Distinct gene expression by expanded clones of quiescent memory CD4+ T cells harboring intact latent HIV-1 proviruses.
Weymar GHJ; Bar-On Y; Oliveira TY; Gaebler C; Ramos V; Hartweger H; et al.
Cell reports · 2022 Sep 06
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells.
Stevenson EM; Terry S; Copertino D; Leyre L; Danesh A; Weiler J; et al.
Nature communications · 2022 Aug 19
Attenuated HIV-1 Nef But Not Vpu Function in a Cohort of Rwandan Long-Term Survivors.
Umviligihozo G; Mann JK; Jin SW; Mwimanzi FM; Hsieh HA; Sudderuddin H; et al.
Frontiers in virology (Lausanne, Switzerland) · 2022 Jun
Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses.
Linden N; Jones RB
Trends in immunology · 2022 Aug
Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen.
Pedersen SF; Collora JA; Kim RN; Yang K; Razmi A; Catalano AA; et al.
Journal of virology · 2022 Jul 13
No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART.
Ward AR; Thomas AS; Stevenson EM; Huang SH; Keating SM; Gandhi RT; et al.
AIDS (London, England) · 2022 Oct 01
Deep Sequencing Analysis of Individual HIV-1 Proviruses Reveals Frequent Asymmetric Long Terminal Repeats.
Joseph KW; Halvas EK; Brandt LD; Patro SC; Rausch JW; Chopra A; et al.
Journal of virology · 2022 Jul 13
Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins.
Zhang F; Zang T; Stevenson EM; Lei X; Copertino DC; Mota TM; et al.
bioRxiv : the preprint server for biology · 2022 May 26
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; et al.
The Lancet. Microbe · 2022 Mar
Prolonged viral suppression with anti-HIV-1 antibody therapy.
Gaebler C; Nogueira L; Stoffel E; Oliveira TY; Breton G; Millard KG; et al.
Nature · 2022 Jun
Hide and seek: for HIV-infected CD4+ T cells, playing well comes with maturity.
Leyre L; Jones RB
The Journal of clinical investigation · 2022 Apr 01
Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones.
Collora JA; Liu R; Pinto-Santini D; Ravindra N; Ganoza C; Lama JR; et al.
Immunity · 2022 Jun 14
The loud minority: Transcriptionally active HIV-1-infected cells survive, proliferate, and persist.
Collora JA; Ho YC
Cell · 2022 Jan 20
Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.
Cho A; Gaebler C; Olveira T; Ramos V; Saad M; Lorenzi JCC; et al.
Proceedings of the National Academy of Sciences of the United States of America · 2022 Jan 25
HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; et al.
mBio · 2021 Dec 21
Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence.
Huang AS; Ramos V; Oliveira TY; Gaebler C; Jankovic M; Nussenzweig MC; et al.
The Journal of experimental medicine · 2021 Dec 06
No publications match these filters. Try another search or choose all years and records.